Teva gets a taste of its own patent-challenge medicine

Teva Pharmaceutical Industries, the generic-drug giant that made a business out of challenging the valuable patents of Big Pharma, is getting a taste of its own tactics as generics makers target its multiple sclerosis drug Copaxone. And it's adopting the same defensive tactics that branded drugmakers have employed against it for years. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.